Belite Bio Inc ADR (NASDAQ:BLTE) — Market Cap & Net Worth
Market Cap & Net Worth: Belite Bio Inc ADR (BLTE)
Belite Bio Inc ADR (NASDAQ:BLTE) has a market capitalization of $6.17 Billion ($6.17 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3114 globally and #1069 in its home market, demonstrating a -2.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Belite Bio Inc ADR's stock price $164.45 by its total outstanding shares 37514630 (37.51 Million). Analyse Belite Bio Inc ADR (BLTE) cash conversion ratio to see how efficiently the company converts income to cash.
Belite Bio Inc ADR Market Cap History: 2022 to 2026
Belite Bio Inc ADR's market capitalization history from 2022 to 2026. Data shows growth from $1.13 Billion to $5.81 Billion (98.98% CAGR).
Index Memberships
Belite Bio Inc ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.26% | #65 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.02% | #337 of 3165 |
Weight: Belite Bio Inc ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Belite Bio Inc ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Belite Bio Inc ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BLTE by Market Capitalization
Companies near Belite Bio Inc ADR in the global market cap rankings as of May 2, 2026.
Key companies related to Belite Bio Inc ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Belite Bio Inc ADR Historical Marketcap From 2022 to 2026
Between 2022 and today, Belite Bio Inc ADR's market cap moved from $1.13 Billion to $ 5.81 Billion, with a yearly change of 98.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.81 Billion | -3.19% |
| 2025 | $6.00 Billion | +153.50% |
| 2024 | $2.37 Billion | +37.92% |
| 2023 | $1.72 Billion | +51.77% |
| 2022 | $1.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Belite Bio Inc ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.17 Billion USD |
| MoneyControl | $6.17 Billion USD |
| MarketWatch | $6.17 Billion USD |
| marketcap.company | $6.17 Billion USD |
| Reuters | $6.17 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Belite Bio Inc ADR
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more